Other Targets in Ovarian Cancer

Michael Birrer, MD, PhD, professor of medicine, Harvard Medical School, director, Gillette Center for Gynecologic Oncology, Massachusetts General Hospital, discusses other targets in ovarian cancer besides PARP.

Clinical Pearls

Michael Birrer, MD, PhD, professor of medicine, Harvard Medical School, director, Gillette Center for Gynecologic Oncology, Massachusetts General Hospital, discusses other targets in ovarian cancer besides PARP.

  • There is an ongoing debate concerning the ideal use and efficacy of antiangiogenic agents outside of bevacizumab
  • The folate receptor is a validated target in ovarian cancer
  • Ovarian cancer has not been as well characterized and developed in the immunotherapy space compared to melanoma or renal cell carcinoma